HMOX1 and non-small cell lung carcinoma: Yu et al. demonstrated that the inhibition of the Nrf2/HO-1 axis makes non-small-cell lung cancer sensitive to epigallocatechin-3-gallate (EGCG) therapy [52], as HO-1 promotes resistance to EGCG-induced apoptosis.